BFRI vs DERM vs SKIN vs PRGO vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 12.

4% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). McKesson Corporation (MCK) offers the better valuation at 19. 2x trailing P/E (16. 7x forward), making it the more compelling value choice. Analysts rate Journey Medical Corporation (DERM) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Perrigo Company plc is actually cheaper at 5.

5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +270.

4%, compared to -98. 7% for Biofrontera Inc. (BFRI). Over 10 years, the gap is even starker: MCK returned +339. 0% versus BFRI's -98. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Journey Medical Corporation's 1. 78β — meaning DERM is approximately -10971% more volatile than MCK relative to the S&P 500. On balance sheet safety, Biofrontera Inc. (BFRI) carries a lower debt/equity ratio of 59% versus 6% for The Beauty Health Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 12.

4% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: Biofrontera Inc. grew EPS 100. 0% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, MCK leads at 13. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

McKesson Corporation (MCK) is the more profitable company, earning 1.

2% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 1. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRGO leads at 8. 1% versus -27. 2% for BFRI. At the gross margin level — before operating expenses — BFRI leads at 75. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Perrigo Company plc (PRGO) trades at 5.

5x forward P/E versus 69. 9x for Journey Medical Corporation — 64. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 209. 1% to $36. 20.

In this comparison, PRGO (9.

8% yield), MCK (0. 4% yield) pay a dividend. BFRI, DERM, SKIN do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, McKesson Corporation (MCK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.

02), +339. 0% 10Y return). Journey Medical Corporation (DERM) carries a higher beta of 1. 78 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (MCK: +339. 0%, DERM: -46. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BFRI (Healthcare) and DERM (Healthcare) and SKIN (Consumer Defensive) and PRGO (Healthcare) and MCK (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BFRI is a small-cap quality compounder stock; DERM is a small-cap quality compounder stock; SKIN is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; MCK is a mid-cap quality compounder stock. PRGO pays a dividend while BFRI, DERM, SKIN, MCK do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.